Search results for "Lymph"

showing 10 items of 4590 documents

Cationic lipide mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modula…

1996

Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. CD34-positive cells were purified by positive and negative selection and cultured in liquid culture for 7 days. These cells were then incubated with ODNs, either alone or in combination with cationic lipids. The uptake of ODNs was enhanced by the use of cationic lipids. In addition, very low concentrations of ODNs in combination with cationic lipids were capable of specifically inhibiting the expression of the c-abl gene. In contrast, no effects were seen on the expression of bcr. However, despite the effective blocking of c-a…

medicine.medical_specialtyCell Membrane PermeabilityChemical PhenomenaMolecular Sequence DataRibonuclease HAntigens CD34BiologyTransfectionPolymerase Chain ReactionCationsProto-Oncogene Proteinshemic and lymphatic diseasesInternal medicineGene expressionmedicineHumansCation Exchange ResinsRNA NeoplasmProto-Oncogene Proteins c-ablGeneCells CulturedOncogene ProteinsABLHematologyBase SequenceCell-Free SystemChemistry PhysicalCell growthCationic polymerizationbreakpoint cluster regionBiological Transporthemic and immune systemsHematologyGeneral MedicineOligonucleotides AntisenseProtein-Tyrosine Kinasesrespiratory systemHematopoietic Stem CellsLipidsMolecular biologyHaematopoiesisGene Expression RegulationDepression ChemicalLiposomesProto-Oncogene Proteins c-bcrAnnals of Hematology
researchProduct

Dihydrocucurbitacin B, isolated from Cayaponia tayuya, reduces damage in adjuvant-induced arthritis

2005

23,24-Dihydrocucurbitacin B, from the anti-rheumatic plant Cayaponia tayuya, was tested on arthritis induced by adjuvant to corroborate the anti-inflammatory properties of this plant. Arthritis was induced in Lewis rats; the resulting arthritic rats were then treated with dihydrocucurbitacin B (1 mg/kg orally, daily, 1 week). The effect of dihydrocucurbitacin B on the synthesis, release, and activity of pro-inflammatory enzymes (elastase, cyclooxygenase-2, and nitric oxide synthase-2) as well as its effect on different mediators (tumor necrosis factor-alpha and interleukin-1beta) were determined. Dihydrocucurbitacin B modified the evolution of the clinical symptoms, reducing the swelling an…

medicine.medical_specialtyCell Survivalmedicine.medical_treatmentAnti-Inflammatory AgentsAdministration OralNitric Oxide Synthase Type IIPainArthritisPlant RootsDinoprostoneCell LineNitric oxidechemistry.chemical_compoundSuperoxidesInternal medicinemedicineAnimalsLymphocytesNitritesPharmacologyDose-Response Relationship DrugPancreatic ElastasebiologyPlant Extractsbusiness.industryMacrophagesElastasemedicine.diseasebiology.organism_classificationArthritis ExperimentalTriterpenesCayaponia tayuyaRatsEnzyme ActivationNitric oxide synthaseCucurbitaceaeEndocrinologyCytokinechemistryCyclooxygenase 2Rats Inbred LewAntirheumatic AgentsToxicitybiology.proteinCytokinesFemaleTumor necrosis factor alphabusinessPhytotherapyEuropean Journal of Pharmacology
researchProduct

Computer-assisted interpretation of flow cytometry data in hematology.

1996

A computer program has been developed for computer-assisted diagnosis (including subclassification) of flow cytometry data of acute leukaemias and non-Hodgkin lymphomas by means of artificial intelligence. The knowledge base for the system has been formulatedas semantic networks that describe physiological hematopoiesisas well as the pathological situation (eg., aberrant antigen expression) of hematological disorders. The semantic networks reflect the hierarchy of cells and their occurrence in diseases, the normal and pathological antigen expression patterns of cells, cell maturation, and the frequency of cell populations in normal blood and bone marrow. Using these semantic networks, the d…

medicine.medical_specialtyCellBiophysicsExpert SystemsDiseaseCell MaturationPathology and Forensic MedicineFlow cytometryEndocrinologyAntigenInternal medicineMedicineHumansDiagnosis Computer-AssistedPathologicalHematologyLeukemiamedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinReproducibility of ResultsCell BiologyHematologyFlow Cytometrymedicine.anatomical_structureData Interpretation StatisticalImmunologyAcute DiseaseBone marrowbusinessCytometry
researchProduct

Changes in lymphocyte subsets after cardiac surgery in children.

2001

Children undergoing cardiopulmonary bypass (CPB) operations have an increased risk of developing severe infections. Impairment of the immune system may contribute to the development of sequelae such as capillary leaks, pulmonary dysfunction and auto-immune reactions. The objective of this study was to investigate the impact of cardiac surgery with CPB on the immune system of infants and young children. We conducted a prospective study to investigate the changes in circulating lymphocyte subpopulations in a sample of 21 consecutive infants and young children undergoing cardiac surgery for congenital heart disease. The following statistically significant (P<0.05) results were obtained: leucoc…

medicine.medical_specialtyCellular immunityHeart diseaseT-LymphocytesInflammationInfectionsLymphocyte ActivationGastroenterologylaw.inventionNatural killer cellImmunophenotypingLeukocyte CountImmune systemlawRisk FactorsStress PhysiologicalInternal medicineCardiopulmonary bypassMedicineHumansIL-2 receptorProspective StudiesInflammationB-LymphocytesCardiopulmonary Bypassbusiness.industryInfantmedicine.diseaseLymphocyte SubsetsCardiac surgeryKiller Cells Naturalmedicine.anatomical_structurePediatrics Perinatology and Child HealthImmunologymedicine.symptombusinessCell Adhesion MoleculesEuropean journal of pediatrics
researchProduct

Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Con…

2004

Abstract RIC followed by allo-SCT is an effective salvage treatment for some relapsed hematologic malignancies due to the postulated graft versus tumour (GVT) effect. In order to evaluate the quality of the clinical response, we have investigated the molecular status of patients receiving allo-SCT for relapsed disease. Forty-four patients (19 chronic lymphocytic leukemias (CLL), 21 follicular lymphomas (FCL) and 4 small lymphocytic lymphomas (SLL)) were enrolled in a prospective phase II study. The median age was 54 years (range: 32–69 years). The median number of previous chemotherapy regimens was 2 (range: 1–5) and 23% of patients had already failed an auto-SCT. Before transplant 34% of p…

medicine.medical_specialtyChemotherapyCyclophosphamidebusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryGastroenterologyMinimal residual diseaseSurgeryFludarabineTransplantationimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineRefractory Chronic Lymphocytic Leukemiabusinessmedicine.drugBlood
researchProduct

Salvage Therapy of Adult ALL

1996

In a first study (1986 to 1992) the German Relapsing ALL Study Group (GRALLSG) has treated 67 adult patients with a first relapse of ALL. A first phase of induction consisted of vindesine, daunorubicin, asparaginase, and prednisone, a second phase of high-dose cytosine-arabinoside (Hd ara-C) and VP16. Results: 45 CR, 2 PR, 13 failures, 7 early death. 25 patients received a BMT. 10 had an allogeneic BMT in CR, 5 after another relapse or with refractory disease. Of 10 with autologous BMT 8 have been in 2nd CR. Only 4 of all 67 patients are surviving without relapse: One after unrelated BMT (36+mo), two after autologous BMT in 2nd CR (46+, 64+mo), and one after chemotherapy (61+mo). One patien…

medicine.medical_specialtyChemotherapyIfosfamidebusiness.industrymedicine.medical_treatmentSalvage therapymedicine.diseaseGastroenterologyPrednisoneAcute lymphocytic leukemiaInternal medicinemedicinePrednisoloneVindesineIdarubicinbusinessmedicine.drug
researchProduct

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia:…

2002

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complet…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyHematopoietic stem cell transplantationmedicine.diseaseAntimetaboliteSurgerymedicine.anatomical_structureInternal medicineAcute lymphocytic leukemiaCytarabineMedicineIdarubicinBone marrowbusinessSurvival ratemedicine.drugBritish Journal of Haematology
researchProduct

Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults

1988

Abstract Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic o…

medicine.medical_specialtyChemotherapymedicine.drug_classbusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryAntimetaboliteGastroenterologySurgeryRegimenRefractoryAcute lymphocytic leukemiaInternal medicineToxicitymedicineCytarabinebusinessAmsacrinemedicine.drugBlood
researchProduct

Pulmonary metastasectomy in colorectal cancer: a prospective study of demography and clinical characteristics of 543 patients in the Spanish colorect…

2013

Objectives To capture an accurate contemporary description of the practice of pulmonary metastasectomy for colorectal carcinoma in one national healthcare system. Design A national registry set up in Spain by Grupo Espanol de Cirugia Metastasis Pulmonares de Carcinoma Colo-Rectal (GECMP-CCR). Setting 32 Spanish thoracic units. Participants All patients with one or more histologically proven lung metastasis removed by surgery between March 2008 and February 2010. Interventions Pulmonary metastasectomy for one or more pulmonary nodules proven to be metastatic colorectal carcinoma. Primary and secondary outcome measures The age and sex of the patients having this surgery were recorded with the…

medicine.medical_specialtyCirurgia colorectalMediastinal lymphadenopathyColorectal cancerMetastasisMetastasisCarcinoembryonic antigenMetàstasiCàncer colorectalColorectal surgerymedicineCarcinoma1506Prospective cohort studyPathological16941695biologybusiness.industryResearchGeneral surgeryGeneral Medicinemedicine.diseaseColorectal cancerSurgeryOncologybiology.protein1737Metastasectomy1717business
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct